Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRZOVP)

Drug Name

(+/-)-threo-Methylphenidate amide Drug Info

Synonyms

UNII-HS1P4T2LCV; HS1P4T2LCV; CHEMBL1253490; 160707-37-9; 50288-62-5; SCHEMBL14453323; ZINC5934431; BDBM50327105; D-threo-; A-Phenyl-2-piperidineacetamide; AJ-55250; AR,2R)-; FT-0673813; FT-0673810; (D,L)-threo-; (alphaR,2R)-alpha-Phenyl-2-piperidineacetamide; AR,2R)-rel-; (D,L)-threo-alpha-Phenyl-2-piperidineacetamide; alpha-Phenyl-2-piperidineacetamide, threo-(+)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 11085277
CAS Number: CAS 160707-37-9
TTD Drug ID: DMRZOVP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dopamine transporter (DAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[2]
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
Methylphenidate	DM7SJD6	Attention deficit hyperactivity disorder	6A05.Z	Approved	[4]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[5]
Phenmetrazine	DMXYTN9	Obesity	5B81	Approved	[6]
Ioflupane i-123	DMNARJT	Parkinson disease	8A00.0	Approved	[7]
DEXMETHYLPHENIDATE HYDROCHLORIDE	DM8WBAH	Attention deficit hyperactivity disorder	6A05.Z	Approved	[8]
Altropane	DMO9WDS	Attention deficit hyperactivity disorder	6A05.Z	Approved	[9]
Amitifadine	DMS1X67	Obesity	5B81	Phase 3	[10]
NAV5001	DMRSI1M	Dementia	6D80-6D86	Phase 3	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine transporter (DAT)	TTVBI8W	SC6A3_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38.
2	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
3	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
4	Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
9	Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).